4SC
4SC is a listed German biotechnology company founded in 1997 in Planegg-Martinsried, near Munich. It applied to the EMA for its HDAC inhibitor resminostat (Kinselby) in advanced mycosis fungoides and Sézary syndrome and received a negative opinion in May 2025.
Overview
4SC is a public company based in Martinsried, Germany, founded in 1997 (Wikidata Q238181, which also gives its website). The EMA product page for Kinselby (resminostat, orphan designation) names 4Sc AG as the marketing authorisation applicant; the CHMP adopted its opinion on 22 May 2025 and the opinion status is negative, so the product is not authorised. It sponsors no trial recorded in OnCo.
Scorecard
All companies- targets +2
- modalities +2
- 24-month regulatory events +2
Resminostat is an oral drug of the HDAC inhibitor class, proposed for advanced mycosis fungoides and Sézary syndrome, two cutaneous T-cell lymphomas. Europe's medicines committee said no to it in May 2025, so it is not authorised.
Similar pages
not linked directly; found by shared links- TreatmentRomidepsin
Shares Resminostat, Histone deacetylases (HDAC), Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- TreatmentVorinostat
Shares Histone deacetylases (HDAC), Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- TreatmentBelinostat
Shares Histone deacetylases (HDAC), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).